CGEM Q2 2023 Earnings — Cullinan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CGEMCullinan Therapeutics, Inc.

$894M

Q2 2023 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$38M

Net Income

-$32M

EPS (Diluted)

$-0.81

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$522M

Total Liabilities

$22M

Stockholders' Equity

$500M

Cash & Equivalents

$142M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$38M	$240M	-115.7%
Net Income	-$32M	$175M	-118.4%